meningococcal polysaccharide diphtheria toxoid conjugate vaccine

REMS

Active immunization to prevent against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity to meningococcal polysaccharide, diphtheria toxoid or latex;
Bleeding disorders (hemophilia, thrombocytopenia, concurrent anticoagulants), unless precautions are taken;
Latex allergy (stopper contains latex).

Use Cautiously in:

Guillain-Barré syndrome
OB: Use during pregnancy only if clearly needed (pregnancy registry participation recommended);
Lactation: Use while breastfeeding only if clearly needed;
Pedi: Children <9 mo (safety and effectiveness not established);
Geri: Safety not established.

Adv. Reactions/Side Effects ⬆ ⬇

GI: diarrhea (Menveo), anorexia, vomiting (Menveo)

Local: pain at injection site, induration, redness, swelling

MS: arthralgia

Neuro: irritability (Menveo), fatigue, headache, malaise, syncope (Menveo)

Resp: apnea in premature infants (Menveo)

Misc: Guillain Barré Syndrome, ANAPHYLAXIS (MENVEO), chills

Interactions ⬆ ⬇

Drug-drug:

Immunosuppressants, antineoplastics, or radiation therapy may ↓ antibody response to and ↑ risk of adverse reactions from vaccines.
May ↓ response to pneumococcal vaccine when concurrently administered

Availability ⬆ ⬇

Solution for injection: 0.5 mL/vial

Route/Dosage ⬆ ⬇

Menactra

IM (Adults and Children 2–55 yr): 0.5 mL single dose.
IM (Children 9–23 mo): 0.5 mL initially, then 0.5 mL 3 mo later.

Menveo

IM (Adults and Children 11–55 yr): 0.5 mL single dose.
IM (Children 2–10 yr): 0.5 mL single dose; if patients 2–5 yr are at continued high risk for meningococcal disease, may administer another dose at 2 mo after the first dose.
IM (Children 7–23 mo): 0.5 mL initially, then 0.5 mL in the second yr of life and ≥3 mo after the first dose.
IM (Children 2 mo): 0.5 mL administered at 2, 4, 6, and 12 mo of age.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Induces production of antibodies to several pathologic serogroups of Neisseria meningitidis.

Therapeutic effects:

Prevention of invasive meningococcal disease.

Classifications ⬆ ⬇

Therapeutic Classification: vaccines/immunizing agents

Pharmacologic Classification: antigens

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed from IM sites.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(antibody presence)

ROUTE	ONSET	PEAK	DURATION
IM	unknown	4 wk	unknown

Patient/Family Teaching ⬆ ⬇

Inform patient of purpose of vaccine.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding prior to administration. Patients who are pregnant or become aware they were pregnant the time of the Menactra immunization, should contact health care professional or Sanofi Pasteur Inc. at 1-800-822-2463 for information about the Pregnancy Exposure Registry.

section name header

Indications ⬇